LDLR and atherosclerosis: In conclusion, we have shown that PRMT5 inhibition by chronic low dose GSK3326595 treatment does not affect atherosclerosis development and lesion composition in Western‐type diet‐fed LDL receptor knockout mice, while it does induce hepatic triglyceride accumulation.